Published in Vaccine Weekly, May 11th, 2005
According to a study from the United States, "Twelve peptides derived from melanocyte differentiation proteins and cancer-testis antigens were combined and administered in a single mixture to patients with resected stage 1113, 111, or IV melanoma. Five of the 12 peptides included in this mixture had not previously been evaluated for their immunogenicity in vivo following vaccination. We report in this study that at least three of these five...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly